Ratings SI-BONE, Inc. BOERSE MUENCHEN

Equities

2K3

US8257041090

Market Closed - BOERSE MUENCHEN Other stock markets 01:14:08 08/06/2024 am IST			5-day change	1st Jan Change
12.3 ^EUR	0.00%		-4.65%	-36.60%

14/05	Transcript : SI-BONE, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
07/05	Morgan Stanley Trims Price Target on SI-Bone to $25 From $26, Keeps Overweight Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SI-BONE, INC.	-36.60%	55Cr	-
SHOCKWAVE MEDICAL	+75.69%	1.26TCr	B-
PENUMBRA, INC.	-24.88%	732.46Cr	C+
MASIMO CORPORATION	+7.04%	666.01Cr	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+15.10%	550.32Cr	D+
GETINGE AB	-15.87%	487.63Cr	B
APT MEDICAL INC.	+14.96%	410.16Cr	-
ASAHI INTECC CO., LTD.	-21.75%	389.36Cr	B-
NOVOCURE LIMITED	+44.01%	231.36Cr	C-
SKAN GROUP AG	+1.98%	206.72Cr	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes